英国儿童肿瘤中卡铂治疗药物监测十余年经验
本文总结了英国在儿童肿瘤患者中开展卡铂治疗药物监测的十余年经验,重点关注新生儿和婴儿、无肾患者及接受高剂量化疗的预后不良患者等特殊人群。通过治疗药物监测旨在一致地达到目标药物暴露、最大化疗效并最小化治疗相关副作用,并指出基于药理学原理的自适应给药可能优于当前基于年龄或体重的减量方案。
要点
- 卡铂药理学暴露与临床反应和毒性之间存在明确关系。
- 新生儿和婴儿、无肾患者及接受高剂量化疗的预后不良患者是剂量挑战人群。
- 治疗药物监测有助于个体化给药并可能推动未来给药方案的开发。
核心结论
- 在儿童肿瘤特殊人群中开展卡铂治疗药物监测已积累显著经验,有助于一致达到目标暴露并优化疗效与安全性。
研究设计与样本
- 本文为英国儿童肿瘤背景下卡铂治疗药物监测十余年经验的总结性文章。
主要发现
- 卡铂的药理学暴露与临床反应和毒性之间存在明确关系。
- 新生儿和婴儿、无肾患者及接受高剂量化疗的预后不良患者是卡铂给药的挑战人群。
- 针对这些人群目前使用非标准化疗方案,临床研究方案与治疗中心之间常采用不同方法。
- 英国已开展治疗药物监测以一致达到目标药物暴露、最大化疗效并最小化治疗相关副作用。
- 一项正在进行的临床试验正在为这些难治患者人群中的多种抗癌药物提供药物暴露信息。
临床怎么用
- 对新生儿和婴儿、无肾患者及接受高剂量化疗的预后不良患者等特殊人群,可考虑采用治疗药物监测指导卡铂个体化给药。
- 当前基于年龄或体重的新生儿和婴儿减量方案,可能更适合替换为基于药理学原理的给药方案。
- 儿童肿瘤中卡铂自适应给药的 successful 应用应鼓励在肿瘤领域更广泛地发展治疗药物监测方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The widely used platinum agent carboplatin represents a good example of an anticancer drug where clear relationships between pharmacological exposure and clinical response and toxicity have previously been shown. Within the setting of childhood cancer, there are defined groups of patients who present a particular challenge when dosing with carboplatin, including neonates and infants, those who are anephric, and poor prognosis patients receiving high-dose chemotherapy. For these groups, nonstandard chemotherapy dosing regimens are currently utilised, often with different approaches between clinical study protocols and between treatment centres. For the treatment of these patient populations in the UK, there is now significant experience in carrying out therapeutic drug monitoring, aiming to consistently achieve target drug exposures, maximise drug efficacy and minimise treatment-related side effects. An ongoing clinical trial is currently providing information on drug exposure for a wide range of anticancer agents in these hard to treat patient populations. In addition to supporting dosing decisions for individual patients, the collection and analysis of these data may allow the development of future dosing regimens. For example, current reduced dosing approaches for neonates and infants based on age or body weight, may well be better replaced by regimens based on a sound pharmacological rationale. The successful use of adaptive carboplatin dosing in childhood cancer should encourage the development of therapeutic drug monitoring approaches more widely in an oncology setting.
引用
- Barnett S, Kong J, Makin G, et al. Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom. Br J Clin Pharmacol. 2020. PMID: 32519769. doi:10.1111/bcp.14419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。